Gc America INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$2.7Mgeneral payments (2019-2025)
$21Kresearch payments (2019-2025)
10,778clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- G-Aenial $892K associated (2023-2025)
- Mi Paste $509K associated (2023-2025)
- Equia $411K associated (2023-2025)
- G-Cem $289K associated (2023-2025)
- Experience $166K associated (2023-2025)
- Gc Fujicem $49K associated (2023-2025)
- Gc Fuji $33K associated (2023-2025)
- G-Premio Bond $25K associated (2023-2025)
- Mipaste One $23K associated (2023-2025)
- Chic $22K associated (2023-2025)
- Saliva-Check $20K associated (2023-2025)
- Legend $17K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Brian Novy | Newhall, CA | Dentist | $255,036.78 |
| Antonino Secchi | Devon, PA | Orthodontics and Dentofacial Orthopedics | $148,149.93 |
| Jeanette Maclean | Glendale, AZ | Pediatric Dentistry | $102,982.58 |
| Marc Geissberger | Greenbrae, CA | General Practice (Dentist) | $97,418.19 |
| Timothy Bizga | Parma, OH | Dentist | $85,976.98 |
| Miles Cone | Portland, ME | Prosthodontics | $78,631.55 |
| Todd Snyder | Laguna Niguel, CA | Dentist | $75,478.73 |
| Robert Marus | Yardley, PA | General Practice (Dentist) | $69,341.72 |
| Matthew Nejad | West Hollywood, CA | General Practice (Dentist) | $69,177.07 |
| Thomas Dudney | Alabaster, AL | Dentist | $68,570.90 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.